Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merrimack Pharma

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

Ipsen buys rare disease group Clementia in $1.3bn deal

Will acquire lead multiple rare disease candidate palovarotene

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival

- PMLiVE

CMS proposes coverage scheme for CAR-T therapies

Proposal says it would improve access to CAR-Ts

- PMLiVE

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

AstraZeneca AZ

US, EU regulators back rapid reviews of AZ’s RSV med

Positive top-line data triggered speedy assessments

- PMLiVE

GSK’s Advair Diskus faces first generic in US

Analysts predict around $250m in sales for Wixela Inhub this year

Credit Score

Asking patients to prove they can pay for healthcare is inhumane. Period.

- PMLiVE

GSK upbeat on its return to oncology market

Zejula signals comeback after four year hiatus

- PMLiVE

AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

Underlines importance of cancer drugs to company's future growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links